Biotechnology Cancer Cures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who started this subject	8/7/2000 10:51:56 AM
From: PL Wilson	of 226

Genta Announces Orphan Drug Designation From Food and Drug Administration and Completes Strategic Review for Its Lead Compound, Genasense(TM).Updated results of the study have been submitted for publication in a leading scientific journal. The initial clinical study showed major responses and unexpectedly prolonged survival (i.e. median in excess of 13 months) in patients with advanced melanoma who were treated with Genasense plus dacarbazine, a standard drug used in the disease.Any comments ???(http://biz.yahoo.com/prnews/000807/ma_genta_f.html

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next